Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GOT1 | P17174 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046101 | 0.77 | KDM4E (0.54) | GRM5CYP1A2SMN1; SMN2 | |
| SCHEMBL29442588 | 0.76 | GOT1 (0.46) | GRM5GOT1DHODHHTR2CCYP1A2 | |
| SCHEMBL1456807 | 0.76 | GOT1 (0.46) | GRM5GOT1DHODHHTR2CCYP1A2 | |
| SCHEMBL30792004 | 0.76 | GOT1 (0.46) | GRM5GOT1DHODHHTR2CCYP1A2 | |
| SCHEMBL10282499 | 0.75 | CYP2E1 (0.39) | HTR2CSMN1; SMN2 | |
| SCHEMBL11849360 | 0.75 | RAB9A (0.42) | SMN1; SMN2 | |
| SCHEMBL27790048 | 0.75 | SMN1; SMN2 (0.39) | GRM5DHODHCYP1A2SMN1; SMN2 | |
| SCHEMBL27790050 | 0.75 | DHODH (0.34) | GRM5DHODH | |
| SCHEMBL10243416 | 0.75 | MEN1 (0.56) | SMN1; SMN2 | |
| SCHEMBL12571308 | 0.74 | HCAR2 (0.43) | DHODHCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | GRM5 4381/4885GOT1 4102/4885DHODH 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.